United Kingdom Early Detection Initiative (UK-EDI) : protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer

Oldfield, Lucy and Stott, Martyn and Hanson, Robert and Jackson, Richard J and Reynolds, William and Chandran-Gorner, Vatshala and Van Der Meer, Robert and Alison, Laurence and Tejeiro, Ricardo and Purewal, Tejpal and Ghaneh, Paula and Palmer, Daniel and Greenhalf, William and Halloran, Chris and Costello, Eithne (2022) United Kingdom Early Detection Initiative (UK-EDI) : protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer. BMJ open, 12 (10). e068010. ISSN 2044-6055 (https://doi.org/10.1136/bmjopen-2022-068010)

[thumbnail of Oldfield-etal-BMJO-2022-United-Kingdom-Early-Detection-Initiative-UK-EDI-protocol-for-establishing-a-national-multicentre-cohort]
Preview
 Text. Filename: Oldfield_etal_BMJO_2022_United_Kingdom_Early_Detection_Initiative_UK_EDI_protocol_for_establishing_a_national_multicentre_cohort.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (540kB)| Preview

Abstract

INTRODUCTION: Pancreatic cancer is a leading cause of cancer deaths worldwide. Screening for this disease has potential to improve survival. It is not feasible, with current screening modalities, to screen the asymptomatic adult population. However, screening of individuals in high-risk groups is recommended. Our study aims to provide resources and data that will inform strategies to screen individuals with new-onset diabetes (NOD) for pancreatic cancer. METHODS AND ANALYSIS: The United Kingdom Early Detection Initiative (UK-EDI) for pancreatic cancer is a national, prospective, observational cohort study that aims to recruit 2500 individuals with NOD (<6 months postdiagnosis) aged 50 years and over, with follow-up every 6 months, over a 3-year period. For study eligibility, diagnosis of diabetes is considered to be clinical measurement of haemoglobin A1c ≥48 mmol/mol. Detailed clinical information and biospecimens will be collected at baseline and follow-up to support the development of molecular, epidemiological and demographic biomarkers for earlier detection of pancreatic cancer in the high-risk NOD group. Socioeconomic impacts and cost-effectiveness of earlier detection of pancreatic cancer in individuals with NOD will be evaluated. The UK-EDI NOD cohort will provide a bioresource for future early detection research to be conducted. ETHICS AND DISSEMINATION: The UK-EDI study has been reviewed and approved by the London-West London and GTAC Research Ethics Committee (Ref 20/LO/0058). Study results will be disseminated through presentations at national and international symposia and publication in peer-reviewed, Open Access journals.

  • Item type:Article
    ID code:82817
    Dates:
    Date
    Event
    10 October 2022
    Published
    10 October 2022
    Published Online
    10 October 2022
    Accepted
    Subjects:Medicine
    Department:University of Strathclyde > University of Strathclyde
    Depositing user: Pure Administrator
    Date deposited:18 Oct 2022 11:01
    Last modified:13 Apr 2024 00:37
    URI:https://strathprints.strath.ac.uk/id/eprint/82817
CORE (COnnecting REpositories)